Fermentalg (FALG) Q1 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 TU earnings summary
5 May, 2026Executive summary
Achieved record Q1 2026 turnover of €3.7 million, surpassing previous Q1 highs.
Sales diversification strategy succeeded, with strong growth in high-margin segments.
Commercial launches of QRIGINST EPA/DHA range and Galdieria Blue expected to impact H2 2026.
Reaffirmed ambition to reach €20 million turnover in 2026.
Financial highlights
Q1 2026 revenue reached €3.7 million, up from €3.6 million in Q1 2025.
Sales excluding aquaculture grew 42% year-over-year, from €2.6 million to €3.7 million.
Temporary shift away from low-margin aquaculture segment.
Outlook and guidance
Anticipates sharp acceleration in growth in H2 2026 due to new product launches.
Maintains target of €20 million in annual revenue for 2026.
Potential return to aquaculture segment by year-end as economic competitiveness improves.
Latest events from Fermentalg
- Record revenue, improved net loss, and new products set the stage for accelerated 2026 growth.FALG
H2 20252 Apr 2026 - Record 2025 revenue and strategic investments position for strong growth and €20M target in 2026.FALG
Q4 2025 TU28 Jan 2026 - Revenue growth, new product launches, and global expansion set the stage for 2026.FALG
Q3 2025 TU7 Oct 2025 - H1 2025 revenue up 20% year-over-year, with strategic milestones and improved net loss.FALG
H1 202511 Sep 2025 - Sales up 20% in H1 2025, with new product approvals and no outstanding convertible debt.FALG
H1 2025 TU8 Jul 2025 - Sales surged nearly threefold year-over-year, with 2024 targets reaffirmed.FALG
Q3 2024 TU13 Jun 2025 - Sales up 2.7x and cash boosted by capital raise, with strategic partnerships accelerating.FALG
H1 202413 Jun 2025 - Record sales and a strengthened HuvePharma alliance drive Fermentalg's 2024 growth.FALG
Q2 2024 TU13 Jun 2025 - Q1 2025 revenue surged 36% as Fermentalg expands into new sustainable markets.FALG
Q1 2025 TU6 Jun 2025